TOKISAKE-ASSOCIATION
20.11.2020 11:32:10 CET | Business Wire | Press release
The Tokisake Association (located in Kyoto Prefecture, President, Tokubee Masuda) was established in August 2019 with the aim of reviving the culture of aged sake and establishing and further enhancing the value of sake to the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005313/en/
The company will sell the highest-priced product in the history of Japanese sake, “Toki no Shirabe” in a limited edition of 20 sets of 8 bottles (720 ml) for 2,020,000 yen, for domestic and international customers to commemorate the establishment of the Association.
In addition to seven bottles of secret sake commercialized from each of the seven breweries that are the founding members of the Association, another very rare bottle is an assemblage (blend) by the world-renowned sommelier Mr. Shinya Tasaki, to complete a limited edition of eight bottles.
By releasing this ultra-gorgeous new product, which is a collection of excellent products engraved over the years, they will continue to contribute to the creation of even more value for Japanese sake in Japan and abroad.
[New Product Overview]
Product Name: [Special Limited] Aged sake set of 8 bottles of "Toki no Shirabe"
Price: 2.02 million yen
Booking period: November 24 (Tuesday) to December 5 (Saturday)
Pre-orders are accepted at: Shusaron.com (https://shusaron-online.com/shopdetail/000000000042/
).
If the number of reservation requests exceeds 20, eligible purchasers will be selected by lottery. The set’s gift box is an original work of art by Yoshizawa Ryoichi, an artisan, and is “made of rice husks that are removed during the brewing process and finished with lacquer based on the shape of a traditional Japanese stacked box,” according to Yoshizawa.
[Limited release 8 bottles of sake]
- Masuda Tokubee Shoten Co., Ltd. / Kyoto: “Tsukino Katsura” 1999
- Kokuryu Sake Brewing Corporation / Fukui: Kokuryu "Muni" Junmai Daiginjo Genshu 1996
- DEWAZAKURA SAKE BREWERY CO.,LTD / Yamagata: "Dewazakura Daiginjo Daikoshu cold aged” 1990 & 1986
- Nanbu Bijin Co., Ltd. / Iwate: "Nanbu Bijin All Koji" Junmai 1998
- Shimazaki Shuzo Co., Ltd. / Tochigi: "Azumarikishi Uroko" Daiginjo Genshu 1987
- NAGAI SAKE INC. / Gunma: “Mizubasho Shizuku Daiginjo ice aged" 2003
- Kidoizumi Shuzo Co., Ltd. / Chiba: "Kidoizumi Afs" Yamahai Junmai 1984
- Mr. Shinya Tasaki's assemblage blend, "Toki no Shirabe”
https://www.youtube.com/watch?v=B18SYRjMA8c
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom